J&J Gets FDA Nod for Robotic Surgery Device, Enters US Market

Johnson & Johnson (JNJ) announced on Wednesday that it has received marketing authorization from the U.S. Food and Drug Administration (FDA) for its robotic surgery device, marking its entry into the U.S. market. The market is currently dominated by Intuitive Surgical's (ISRG) da Vinci system, which holds over 80% market share.

The Product

J&J's new device is a direct competitor to the da Vinci system. While specific technical details have not been disclosed, the company emphasizes improved flexibility and potential cost reductions.

Pricing and Availability

J&J has not yet announced a commercial launch date or pricing. Analysts expect the device to be priced competitively with da Vinci systems, which cost between $0.5 million and $2.5 million per unit.

Competition

The robotic surgery market is highly competitive, with players like Medtronic (MDT) and Asana Medical (ASAN) also developing systems. The global market was valued at approximately $6 billion in 2025 and is growing at over 15% CAGR.

Potential Impact on J&J

Entering the robotic surgery market diversifies J&J's revenue stream beyond pharmaceuticals and traditional medical devices. While gaining significant market share may take years, it strengthens J&J's position in the high-growth medical device sector.